Literature DB >> 4987169

Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases.

E J Lewis, G J Busch, P H Schur.   

Abstract

36 renal biopsies from patients with nephritis were studied for glomerular localization of the heavy chain subgroups of immunoglobulin G (IgG or gammaG). The deposition pattern of these subgroups was selective and did not reflect the normal serum concentration of these proteins. gammaG2, which comprises 18% of normal serum gammaG, was the predominant or unique subgroup deposited in five cases of lupus nephritis and four biopsies with other forms of nephritis associated with granular gammaG deposits. gammaG3, which normally makes up only 8% of the serum gammaG, was the dominant subgroup seen in one biopsy of lobular glomerulonephritis. Patients with linear gammaG deposits generally had a selective absence of gammaG3 and often had large amounts of gammaG4 (normally 3% of the serum gammaG) deposited. The deposition of complement components C1q, C4, and C3 was variable. One biopsy had only gammaG2 and no complement components in the deposits and had no neutrophile leukocyte infiltration. This latter observation correlates well with the poor ability of gammaG2 to fix complement in vitro. Similarly, deposits containing large amounts of gammaG4, which does not fix complement, also tended to have less inflammatory infiltrate than deposits devoid of this subgroup. The selective deposition of monotypic or restricted gammaG subgroups on the glomerulus supports the likelihood that the gammaG represents antibody. The nature of the subgroup involved in the deposit may represent one variable in the determination of the inflammatory and morphological picture that evolves in human glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4987169      PMCID: PMC322578          DOI: 10.1172/JCI106326

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Zone electrophoresis in a starch supporting medium.

Authors:  H G KUNKEL; R J SLATER
Journal:  Proc Soc Exp Biol Med       Date:  1952-05

2.  Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

Authors:  T Ishizaka; K Ishizaka; S Salmon; H Fudenberg
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

3.  IgA glomerular deposits in renal disease.

Authors:  J Berger
Journal:  Transplant Proc       Date:  1969-12       Impact factor: 1.066

4.  Acute poststreptococcal glomerulonephritis: immune deposit disease.

Authors:  A F Michael; K N Drummond; R A Good; R L Vernier
Journal:  J Clin Invest       Date:  1966-02       Impact factor: 14.808

5.  Immune complex disease. I. Experimental acute and chronic glomerulonephritis.

Authors:  F G Germuth; L B Senterfit; A D Pollack
Journal:  Johns Hopkins Med J       Date:  1967-04

6.  IMMUNOLOGICAL STUDIES OF THE 11S PROTEIN COMPONENT OF THE HUMAN COMPLEMENT SYSTEM.

Authors:  J H MORSE; C L CHRISTIAN
Journal:  J Exp Med       Date:  1964-02-01       Impact factor: 14.307

7.  Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis.

Authors:  F J DIXON; J D FELDMAN; J J VAZQUEZ
Journal:  J Exp Med       Date:  1961-05-01       Impact factor: 14.307

8.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

9.  A ROLE OF POLYMORPHONUCLEAR LEUKOCYTES AND COMPLEMENT IN NEPHROTOXIC NEPHRITIS.

Authors:  C G COCHRANE; E R UNANUE; F J DIXON
Journal:  J Exp Med       Date:  1965-07-01       Impact factor: 14.307

10.  Experimental glomerulonephritis. II. Immunologic events in the pathogenesis of nephrotoxic serum nephritis in the rat.

Authors:  D K HAMMER; F J DIXON
Journal:  J Exp Med       Date:  1963-06-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Autoimmune glomerulotubular nephropathy in mice.

Authors:  W K Bolton; F R Benton; B C Sturgill
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

3.  Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.

Authors:  S Uwatoko; M Mannik
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

4.  Serum IgG4 anti-Fab antibodies in rheumatoid arthritis are constitutively expressed.

Authors:  J E Persselin; R H Stevens
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

5.  Distribution of IgG subclasses in membranous nephropathy.

Authors:  T Doi; M Mayumi; K Kanatsu; F Suehiro; Y Hamashima
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

6.  Glomerular complement components in human glomerulonephritis.

Authors:  P J Verroust; C B Wilson; N R Cooper; T S Edgington; F J Dixon
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

7.  The influence of genotype on the development of glomerular lesions in mink with Aleutian disease virus.

Authors:  M I Johnson; J B Henson; J R Gorham
Journal:  Am J Pathol       Date:  1975-11       Impact factor: 4.307

8.  Antigammaglobulin (rheumatoid factor) activity of human IgG subclasses.

Authors:  F Shakib; D R Stanworth
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

9.  Restriction of human IgG subclass expression in the population of auto-antibodies to glomerular basement membrane.

Authors:  C Bowman; K Ambrus; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis.

Authors:  J L Roberts; M M Schwartz; E J Lewis
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.